{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:00:10Z","timestamp":1753891210650,"version":"3.41.2"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induced the new coronavirus disease 2019 (COVID-19) pandemic worldwide. SARS-CoV-2 vaccines are designed to control the transmission of the disease. However, post-vaccination subacute thyroiditis (SAT) also appears with increase vaccination rate. Three cases of SAT after SARS-CoV-2 vaccines are described in this study. We have reported the patients\u2019 clinical symptoms, laboratory tests, and thyroid imaging. Tests for COVID-19 were all negative, and the patients did not report thyroid-related diseases, autoimmune diseases, or preceding upper respiratory system infections in their medical history. Three female patients showed neck pain on physical examination. The laboratory test results and imaging findings were consistent with the diagnostic criteria of SAT. The patients were carried out a standardized treatment according to their symptoms, and we closely followed up their response to the treatment. Clinicians must be aware of the possibility of SAT after receiving the vaccines and make timely therapy.<\/jats:p>","DOI":"10.3389\/fmed.2022.856572","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T06:07:50Z","timestamp":1659679670000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case report: subacute thyroiditis after receiving SARS-CoV-2 vaccine, maybe not only adjuvants"],"prefix":"10.3389","volume":"9","author":[{"given":"Yizhou","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaowei","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41586-021-03792-w","article-title":"After the pandemic: Perspectives on the future trajectory of COVID-19.","volume":"596","author":"Telenti","year":"2021","journal-title":"Nature."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/j.immuni.2021.07.017","article-title":"Accelerated COVID-19 vaccine development: Milestones, lessons, and prospects.","volume":"54","author":"Bok","year":"2021","journal-title":"Immunity."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1016\/S1473-3099(21)00472-2","article-title":"Prevention of host-to-host transmission by SARS-CoV-2 vaccines.","volume":"22","author":"Mostaghimi","year":"2021","journal-title":"Lancet Infect Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet."},{"key":"B5","doi-asserted-by":"publisher","first-page":"m1091","DOI":"10.1136\/bmj.m1295","article-title":"Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study.","volume":"368","author":"Chen","year":"2020","journal-title":"BMJ."},{"key":"B6","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s12020-021-02770-6","article-title":"SARS-CoV-2 plays a pivotal role in inducing hyperthyroidism of Graves\u2019 disease.","volume":"73","author":"Murugan","year":"2021","journal-title":"Endocrine."},{"key":"B7","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor.","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s11154-021-09648-y","article-title":"New aspects in the pathogenesis and management of subacute thyroiditis.","volume":"22","author":"Stasiak","year":"2021","journal-title":"Rev Endocr Metab Disord."},{"key":"B9","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1089\/105072503322239989","article-title":"The prevalence of elevated serum C-reactive protein levels in inflammatory and noninflammatory thyroid disease.","volume":"13","author":"Pearce","year":"2003","journal-title":"Thyroid."},{"key":"B10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1743-422X-6-5","article-title":"Viruses and thyroiditis: An update.","volume":"6","author":"Desailloud","year":"2009","journal-title":"Virol J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"6191","DOI":"10.2147\/JIR.S332705","article-title":"SARS-CoV-2: Emerging role in the pathogenesis of various thyroid diseases.","volume":"14","author":"Murugan","year":"2021","journal-title":"J Inflamm Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41577-021-00578-z","article-title":"Immunological mechanisms of vaccine-induced protection against COVID-19 in humans.","volume":"21","author":"Sadarangani","year":"2021","journal-title":"Nat Rev Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e16045","DOI":"10.7759\/cureus.16045","article-title":"Subacute thyroiditis after receiving the adenovirus-vectored vaccine for coronavirus disease (COVID-19).","volume":"13","author":"Oyibo","year":"2021","journal-title":"Cureus."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1210\/clinem\/dgab373","article-title":"Three cases of subacute thyroiditis following SARS-CoV-2 vaccine: Postvaccination ASIA syndrome.","volume":"106","author":"l\u0307remli","year":"2021","journal-title":"J Clin Endocrinol Metab."},{"key":"B15","doi-asserted-by":"publisher","first-page":"4090","DOI":"10.1080\/21645515.2021.1947102","article-title":"Subacute thyroiditis following COVID-19 vaccination in a 67-year-old male patient: A case report.","volume":"17","author":"\u015eahin Tekin","year":"2021","journal-title":"Hum Vaccin Immunother."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S1473-3099(21)00127-4","article-title":"Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: Two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.","volume":"21","author":"Yang","year":"2021","journal-title":"Lancet Infect Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: A randomised, double-blind, placebo-controlled, phase 1\/2 trial.","volume":"21","author":"Xia","year":"2021","journal-title":"Lancet Infect Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"725","DOI":"10.2169\/internalmedicine.47.0740","article-title":"Clinical characteristics of 852 patients with subacute thyroiditis before treatment.","volume":"47","author":"Nishihara","year":"2008","journal-title":"Intern Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"dgaa038","DOI":"10.1210\/clinem\/dgaa038","article-title":"The detection of serum IgMs to thyroglobulin in subacute thyroiditis suggests a protective role of IgMs in thyroid autoimmunity.","volume":"105","author":"Ricci","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"key":"B20","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1159\/000501033","article-title":"Moderate frequency of anti-thyroglobulin antibodies in the early phase of subacute thyroiditis.","volume":"8","author":"Nishihara","year":"2019","journal-title":"Eur Thyroid J."},{"key":"B21","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1007\/BF03345804","article-title":"Thyroglobulin autoantibodies of patients with subacute thyroiditis are restricted to a major B cell epitope.","volume":"35","author":"Latrofa","year":"2012","journal-title":"J Endocrinol Invest."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e244711","DOI":"10.1136\/bcr-2021-244711","article-title":"Subacute thyroiditis after inactive SARS-CoV-2 vaccine.","volume":"14","author":"Sayg\u0131l\u0131","year":"2021","journal-title":"BMJ Case Rep."},{"key":"B23","doi-asserted-by":"publisher","first-page":"101412","DOI":"10.1016\/j.beem.2020.101412","article-title":"ASIA syndrome and endocrine autoimmune disorders.","volume":"34","author":"Bragazzi","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab."},{"key":"B24","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s42000-020-00230-w","article-title":"Subacute thyroiditis in a patient infected with SARS-COV-2: An endocrine complication linked to the COVID-19 pandemic.","volume":"20","author":"Ruggeri","year":"2021","journal-title":"Hormones (Athens)."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s40618-020-01312-7","article-title":"SARS-CoV-2: A potential trigger for subacute thyroiditis? Insights from a case report.","volume":"43","author":"Ippolito","year":"2020","journal-title":"J Endocrinol Invest."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s40618-020-01316-3","article-title":"A case of subacute thyroiditis associated with Covid-19 infection.","volume":"43","author":"Asfuroglu Kalkan","year":"2020","journal-title":"J Endocrinol Invest."},{"key":"B27","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1159\/000511872","article-title":"Subacute thyroiditis from COVID-19 infection: A case report and review of literature.","volume":"9","author":"Khatri","year":"2021","journal-title":"Eur Thyroid J."},{"key":"B28","doi-asserted-by":"publisher","first-page":"dgaa276","DOI":"10.1210\/clinem\/dgaa276","article-title":"Subacute thyroiditis after Sars-COV-2 infection.","volume":"105","author":"Brancatella","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"key":"B29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s40249-020-00662-x","article-title":"Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues.","volume":"9","author":"Li","year":"2020","journal-title":"Infect Dis Poverty."},{"key":"B30","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.cell.2020.04.035","article-title":"SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues.","volume":"181","author":"Ziegler","year":"2020","journal-title":"Cell."},{"key":"B31","doi-asserted-by":"publisher","first-page":"108480","DOI":"10.1016\/j.clim.2020.108480","article-title":"Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases.","volume":"217","author":"Vojdani","year":"2020","journal-title":"Clin Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1080\/21645515.2015.1117716","article-title":"Subacute thyroiditis following seasonal influenza vaccination.","volume":"12","author":"Altay","year":"2016","journal-title":"Hum Vaccin Immunother."},{"key":"B33","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1007\/BF03346633","article-title":"Subacute thyroiditis following the H1N1 vaccine.","volume":"33","author":"Girgis","year":"2010","journal-title":"J Endocrinol Invest."},{"key":"B34","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/s41586-021-04005-0","article-title":"High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape.","volume":"600","author":"Schmidt","year":"2021","journal-title":"Nature."},{"key":"B35","doi-asserted-by":"publisher","first-page":"737142","DOI":"10.3389\/fmed.2021.737142","article-title":"Case report: Two cases of subacute thyroiditis following SARS-CoV-2 vaccination.","volume":"8","author":"Bornemann","year":"2021","journal-title":"Front Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s40618-022-01747-0","article-title":"CoV-2 vaccine-associated subacute thyroiditis: Insights from a systematic review.","volume":"45","author":"Ippolito","year":"2022","journal-title":"J Endocrinol Invest."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.856572\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T06:07:54Z","timestamp":1659679674000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.856572\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,5]]},"references-count":36,"alternative-id":["10.3389\/fmed.2022.856572"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.856572","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2022,8,5]]},"article-number":"856572"}}